A 73-Year-Old Woman with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Expert Matthew Lunning, DO, FACP, reviews the case of a 73-year-old woman with R/R DLBCL, considering current and emerging treatment strategies in this setting.

A comprehensive overview of third-line relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and bispecific antibodies.

Dr. Lunning, an expert in lymphoma, discusses the results and clinical significance of the LOTIS-2 trial, evaluating loncastuximab tesirine for patients with R/R DLBCL.

Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.

Expert shares clinical perspectives and treatment considerations regarding use of later lines of therapy for patients with R/R diffuse large B-cell lymphoma.

A deep dive into treatment sequencing strategies in R/R DLBCL, sharing insights from clinical data and recently approved novel therapies.

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.